Physicians managing chronic migraine may be interested in new comparative patient-reported data from the FORWARD study, which evaluated treatment satisfaction with onabotulinumtoxinA versus topiramate. In...
At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...
The results from a recent randomized controlled trial showed that ultrasound-guided sphenopalatine ganglion (SPG) and greater occipital nerve blocks are equally effective in reducing headache frequency,...
This phase 4 study assessed the long-term safety and tolerability of once-daily oral rimegepant (75 mg) in adults with episodic migraine to inform clinicians about its preventive treatment profile.
A phase 3 randomized trial evaluated the efficacy and safety of fremanezumab for preventive treatment of episodic migraine in children and adolescents, addressing a significant evidence gap in pediatric...
A phase 4 TANDEM trial in the United States evaluated whether ubrogepant for acute migraine treatment can be safely added to atogepant and used daily for preventive therapy in adults with episodic migraine,...
A large cohort study found no significant association between migraines, their subtypes, or frequency and Parkinson disease (PD) risk in women 45 years and older, suggesting migraines may not contribute to...
Results from a recent randomized controlled trial shows that cognitive-behavioral stress management (CBSM) significantly reduces anxiety, depression, and post-traumatic stress disorder in parents of...
The FDA approved the first treatment for patients with congenital thrombotic thrombocytopenic purpura (cTTP), which is a rare and life-threatening blood clotting disorder that may be fatal if left...
